Phase II Study of AZD2171 (NSC 732208) in Combination With Pemetrexed in Relapsed Non-Small Cell Lung Cancer (NOS: 10029514)

Trial Profile

Phase II Study of AZD2171 (NSC 732208) in Combination With Pemetrexed in Relapsed Non-Small Cell Lung Cancer (NOS: 10029514)

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2014

At a glance

  • Drugs Cediranib (Primary) ; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jan 2013 Planned End Date changed from 1 Mar 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
    • 28 Nov 2012 Planned end date changed from 1 Dec 2010 to 1 Mar 2012 as reported by ClinicalTrials.gov.
    • 16 Mar 2012 Planned End Date changed from 1 Jul 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top